Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

ECTRIMS 2021 HIGHLIGHTS – WEDNESDAY, OCTOBER 13 EDITION

October 13, 2021

…ohort. Comorbid NMOSD patients were six-fold more likely to have a poor outcome compared to non-comorbid patients. RIS: stratifying risk of progression An analysis of the RelevarEM MS/NMOSD registry in Argentina (n=88) reported that patients with radiologically isolated syndrome with two or three risk factors were at high risk of progression to CIS/MS (Rojas et al. ECTRIMS 2021; abstracts P006 and P009). Over the 40-month follow-up period, 44.3% s…

COVID vaccination and anti-CD20s – an update

June 28, 2021

…ation may be considered 2-4 weeks after vaccination, whereas >4 weeks is recommended between vaccination and a resumption of ocrelizumab dosing. In addition, the recommendation to consider vaccination >12 weeks after the last ocrelizumab dose would appear to be the minimum duration; a longer delay (4-6 months) may be preferable, in line with the most recent recommendations (31 January) from the Canadian Network of MS Clinics (https://cnmsc.ca/Covi…

SARS-CoV-2 variants – an update

June 16, 2021

…ildren aged 6-9 years (Sheikh et al. Lancet 2021; epublished 14 June 2021; www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01358-1/fulltext). The Delta variant was also associated with an increased risk of hospitalization (hazard ratio 1.85 vs. Alpha cases). However, hospitalization rates were similarly low for both variants in vaccinated individuals. After two doses of the Pfizer-BioNTech vaccine, the effectiveness, defined as preventi…

COVID vaccine interchangeability – what is the evidence?

June 8, 2021

…w been published (Shaw et al. Lancet 2021;397:2043-2046, free full text at www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01115-6/fulltext). Adverse events were more common with the mixed-vaccine regimens. In the group receiving the AstraZeneca vaccine followed by the Pfizer vaccine, adverse events included feverishness (34% vs. 10% for AZ/AZ and 21% for Pfizer/Pfizer); chills (38% vs. 12% for AZ/AZ and 24% for Pfizer/Pfizer); headache…

COVID-19 mortality in MS patients: a systematic review

June 1, 2021

…case mortality rate in Canada and the U.S. is currently 1.8% (worldometer.com). The study did not report the age-adjusted mortality rate but noted that 19.1% of deaths were in MS patients < 50 years and 50.0% of deaths were in individuals aged >60 years. The mortality rate was somewhat higher in patients receiving a B cell-depleting agent (2.5%) compared to other DMTs, such as teriflunomide (1.6%), natalizumab (1.1%), glatiramer acetate (0.8%) an…